<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762681</url>
  </required_header>
  <id_info>
    <org_study_id>NP40520</org_study_id>
    <secondary_id>2018-003530-32</secondary_id>
    <nct_id>NCT03762681</nct_id>
  </id_info>
  <brief_title>A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Randomized, Placebo-controlled,Observer-blinded Study, to Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of RO7239958 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and
      participants diagnosed with chronic hepatitis B (CHB).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">March 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Changes in Vital Signs, Physical Findings and Electrocardiogram (ECG) Findings, and Clinical Laboratory Results</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection Site Reactions (ISRs)</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of RO7239958</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 36, 43, 50, 57, 64, 74 and 78; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of RO7239958</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 36, 43, 50, 57, 64, 74 and 78; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for Various Time Intervals Post-dose</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 36, 43, 50, 57, 64, 74 and 78; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Change from Baseline in Hepatitis B Surface Antigen (HBsAg) Levels</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Change from Baseline in Hepatitis B Surface Antibody (anti-HBs) Levels</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Number of Participants With HBsAg Loss</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Number of Participants With Hepatitis B e Antigen (HBeAg) Loss in Participants HBeAg-positive at Baseline</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Number of Participants With Hepatitis B e Antibody (anti-HBe) Seroconversion in Participants HBeAg-positive at Baseline</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2a, 2b: Number of Participants With HBV DNA Below the Assay Lower Limit of Quantification</measure>
    <time_frame>Part 1: up to 16 weeks, Part 2a: up to 20 weeks, Part 2b: up to 28 weeks</time_frame>
    <description>Part 1: Days 1-6 and Day 8 of Period 1 (Period 1 = 8 days), Day 22 and at early termination. Parts 2a, 2b: Days 1-2, Days 8, 15, 22, Days 29-30; Part 2b: Days 43, 57, 71; Parts 2a, 2b: at discontinuation (DC) and at follow-up visits 14, 28, 56, and 84 days after the last dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hepatitis B Virus Infection</condition>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a: Multi-dose, CHB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CHB will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b: Multi-dose, CHB (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional study arm to open based on data collected from Part 2a. Participants with CHB will be administered different doses and frequencies of RO7239958 or placebo SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7239958</intervention_name>
    <description>Subcutaneous (SC) dose administration as per the schedule specified in the respective arm.</description>
    <arm_group_label>Part 1: Single Ascending Dose, HV</arm_group_label>
    <arm_group_label>Part 2a: Multi-dose, CHB</arm_group_label>
    <arm_group_label>Part 2b: Multi-dose, CHB (Optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous (SC) dose administration as per the schedule specified in the respective arm.</description>
    <arm_group_label>Part 1: Single Ascending Dose, HV</arm_group_label>
    <arm_group_label>Part 2a: Multi-dose, CHB</arm_group_label>
    <arm_group_label>Part 2b: Multi-dose, CHB (Optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Parts

        -Female participants should be of non-childbearing potential and male participants who are
        with pregnant partners or partners of childbearing potential must agree to remain abstinent
        or use contraceptive measures

        Part 1 (SAD HV only)

          -  Healthy, as judged by the Investigator

          -  Non-smoker (nor tobacco containing products) for at least 90 days prior to dosing on
             Day 1, and agrees to remain non-smoker during the study

        Part 2 (CHB only)

          -  Positive serum HBsAg status for &gt; 6 months prior to screening

          -  Serum HBsAg level ≥ 250 IU/mL at screening

          -  On stable entecavir or tenofovir (alone or in combination) treatment and having
             received the same drug in the 3 months prior to randomisation

          -  HBV DNA below the lower limit of quantification (LLQ) for ≥ 6 months prior to
             screening by local testing, and confirmed at screening

          -  Screening laboratory values (including hematology, chemistry, urinalysis) within
             normal ranges

          -  No past or current diagnosis of cirrhosis

        Exclusion Criteria:

        All Parts

          -  History or presence of significant cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological disorders, or diagnosed central or
             peripheral neurological disease, capable of altering the absorption, metabolism, or
             elimination of drugs, or constituting a risk when taking the study treatment, or of
             interfering with the interpretation of the data

          -  History of lymphoma, leukemia, or malignancy within the past five years

          -  Positive for human immunodeficiency virus (HIV) infection

          -  Participant under judicial supervision, guardianship or curatorship

        Part 1 (SAD HV only)

          -  Screening ECG showing clinically relevant abnormalities

          -  Abnormal blood pressure

          -  History or presence of liver disease, or known hepatic or biliary abnormalities

          -  Alanine aminotransferase (ALT) ≥1.5 × upper limit of normal (ULN)

          -  Any clinically significant out of range findings in other laboratory test results or
             any other clinically significant (as judged by the Investigator) abnormalities in the
             physical examination at screening and on Day -1

          -  Positive for hepatitis B surface antigen (HBsAg), or hepatitis B core total antibody
             [anti-HBc]), or hepatitis C virus (HCV) antibody test result

        Part 2 (CHB only)

          -  History or presence of bridging fibrosis or cirrhosis or decompensated liver disease

          -  History or presence of a medical condition associated with liver disease other than
             HBV infection. Other known hepatic or biliary abnormalities

          -  History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) ≥13
             ng/mL

          -  History of having received (in the last six months) or currently receiving any
             systemic antineoplastic (including radiation) or immune-modulatory treatment
             (including systemic corticosteroids)

          -  History of organ transplantation

          -  Estimated glomerular filtration rate (eGFR) &lt;70 mL/min/1.73m^2

          -  Confirmed QT interval corrected using Fridericia's formula (QTcF) &gt;450 ms

          -  Expected to need any other systemic antiviral therapy at any time during participation
             in the study

          -  Positive hepatitis C antibody test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital Ead</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COMAC Medical; Clinical Research Unit for Phase I</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun City</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center.</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szp.Specjalistyczny im.K.Dluskiego w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70457</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

